Biblioteca de referencias

G
ESPACIO de obesidad › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

Descargar en RIS (510 referencias)

Artículos y guías en PubMed (342)

  1. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050-60. doi:10.1001/jama.2013.280521 · PMID 24240932H1
  2. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609-16. doi:10.1056/NEJM199608293350901 · PMID 8692238C5
  3. Abu Dayyeh BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, Thompson CC, Thaemert BC, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022;400(10350):441-451. doi:10.1016/S0140-6736(22)01280-6 · PMID 35908555C9H5
  4. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753-61. doi:10.1056/NEJMoa066603 · PMID 17715409G3
  5. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93-102. doi:10.1161/CIRCULATIONAHA.107.709204 · PMID 18086925H1
  6. American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S216-S245. doi:10.2337/dc26-S010 · PMID 41358899G1
  7. American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S166-S182. doi:10.2337/dc26-S008 · PMID 41358882D4G1
  8. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183-S215. doi:10.2337/dc26-S009 · PMID 41358900G1I1
  9. American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1). doi:10.1136/bmjdrc-2025-005729 · PMID 41529914G1
  10. American Diabetes Association Professional Practice Committee for Obesity. Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity-2026. BMJ Open Diabetes Res Care. 2026;13(Suppl 1). doi:10.1136/bmjdrc-2026-006247 · PMID 42242835G1
  11. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97.e10. doi:10.1053/j.gastro.2015.04.043 · PMID 25935633C10
  12. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636. doi:10.1161/01.CIR.0000134791.68010.FA · PMID 15289388H4
  13. Antza C, Jordan J, McGowan B, Ciudin A, Filippi-Arriaga F, Hoenemann JN, et al. Treating obesity and heart failure: a how-to-manage guide from the European Association for the Study of Obesity and the European Society of Hypertension working group on diabetes and metabolic risk factors. J Hypertens. 2026;44(6):938-947. doi:10.1097/HJH.0000000000004285 · PMID 41818428G1
  14. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-43. doi:10.1002/oby.20309 · PMID 23408728G2
  15. Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31(1):278-285. doi:10.1038/s41591-024-03327-6 · PMID 39455729C10
  16. Aranceta-Bartrina J, Pérez-Rodrigo C, Alberdi-Aresti G, Ramos-Carrera N, Lázaro-Masedo S. Prevalence of General Obesity and Abdominal Obesity in the Spanish Adult Population (Aged 25-64 Years) 2014-2015: The ENPE Study. Rev Esp Cardiol (Engl Ed). 2016;69(6):579-87. doi:10.1016/j.rec.2016.02.009 · PMID 27133458G3H2
  17. Aranceta-Bartrina J, Gianzo-Citores M, Pérez-Rodrigo C. Prevalence of overweight, obesity and abdominal obesity in the Spanish population aged 3 to 24 years. The ENPE study. Rev Esp Cardiol (Engl Ed). 2020;73(4):290-299. doi:10.1016/j.rec.2019.07.023 · PMID 31987815G3
  18. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678 · PMID 30879355B4C4C8D1G1H4
  19. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 · PMID 38078870C4C7G2G5I1
  20. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394 · PMID 40353578C4C7G2I1
  21. Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687. doi:10.1038/s41591-026-04386-7 · PMID 42120723G2G5
  22. Arterburn DE, Olsen MK, Smith VA, Livingston EH, Van Scoyoc L, Yancy WS Jr, et al. Association between bariatric surgery and long-term survival. JAMA. 2015;313(1):62-70. doi:10.1001/jama.2014.16968 · PMID 25562267G3
  23. Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012;345:e4439. doi:10.1136/bmj.e4439 · PMID 22782848C8
  24. Aune D, Schlesinger S, Norat T, Riboli E. Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33(8):711-722. doi:10.1007/s10654-017-0353-9 · PMID 29417316H1
  25. Azran C, Hanhan-Shamshoum N, Irshied T, Ben-Shushan T, Dicker D, Dahan A, et al. Hypothyroidism and levothyroxine therapy following bariatric surgery: a systematic review, meta-analysis, network meta-analysis, and meta-regression. Surg Obes Relat Dis. 2021;17(6):1206-1217. doi:10.1016/j.soard.2021.02.028 · PMID 33839048C9
  26. Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. J Am Coll Cardiol. 2018;72(7):707-717. doi:10.1016/j.jacc.2018.05.049 · PMID 30092946H1
  27. Batal O, Schoenhagen P, Shao M, Ayyad AE, Van Wagoner DR, Halliburton SS, et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(3):230-6. doi:10.1161/CIRCEP.110.957241 · PMID 20504944H1
  28. Baudry G, Biegus J, López-Azor JC, Bozkurt B, Butler J, Cobo-Marcos M, et al. Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular-Kidney-Liver-Metabolic (CVKLM) Multiorgan Staging. Eur J Prev Cardiol. 2026. doi:10.1093/eurjpc/zwag563 · PMID 42945405B7C7C10E3G1H3H4H5
  29. Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026;34(3):537-549. doi:10.1002/oby.70106 · PMID 41508550G5
  30. Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1 · PMID 42810372C7G2G5
  31. Beran A, Shaear M, Al-Mudares S, Sharma I, Matar R, Al-Haddad M, et al. Predictors of marginal ulcer after gastric bypass: a systematic review and meta-analysis. J Gastrointest Surg. 2023;27(6):1066-1077. doi:10.1007/s11605-023-05619-7 · PMID 36795250C9
  32. Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643. doi:10.1016/S0140-6736(25)02155-5 · PMID 41207310G5
  33. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-9. doi:10.1038/ijo.2016.52 · PMID 27005405G2H3I1
  34. Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. doi:10.1056/NEJMoa2403664 · PMID 39476339G2
  35. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018;379(12):1107-1117. doi:10.1056/NEJMoa1808721 · PMID 30145941C5G2
  36. Bozkurt B, le Roux CW, Wharton S, Butt JH, Startseva E, Sumin M, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. doi:10.1016/S0140-6736(26)02140-9 · PMID 43003106C5G2G5
  37. Busetto L, Dicker D, Frühbeck G, Halford JCG, Sbraccia P, Yumuk V, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30(9):2395-2399. doi:10.1038/s41591-024-03095-3 · PMID 38969880B6C4G1
  38. Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635-1648. doi:10.1016/S0140-6736(24)00469-0 · PMID 38599221C5
  39. Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, Køber L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44(13):1136-1153. doi:10.1093/eurheartj/ehad083 · PMID 36944496C7H1
  40. Butt JH, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Gustafsson F, et al. Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox. Eur J Heart Fail. 2025;27(3):527-536. doi:10.1002/ejhf.3424 · PMID 39155576C7
  41. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 · PMID 37622654C3G1H4
  42. Bäck M, Wilhelm M, Marcin T, Machado FVC, Sandberg A, Buccheri S, et al. 2026 ESC Guidelines on cardiac rehabilitation. Eur Heart J. 2026;47(39):5631-5729. doi:10.1093/eurheartj/ehag099 · PMID 42661418B1B4B6C2C3C4C5C6C8C9D1D4E3G1H3H5I1
  43. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol. 2017;70(12):1429-1437. doi:10.1016/j.jacc.2017.07.763 · PMID 28911506H1H5
  44. Carlsson LMS, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M, et al. Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. N Engl J Med. 2020;383(16):1535-1543. doi:10.1056/NEJMoa2002449 · PMID 33053284C9G2H1
  45. Cavender MA, Jastreboff AM, Cheng AYY, Davies MJ, Donaldson L, Gerlach LO, et al. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J. 2026. doi:10.1016/j.ahj.2026.107626 · PMID 42838477G2
  46. Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026;335(5):434-438. doi:10.1001/jama.2025.24288 · PMID 41324410C4C7G1I1
  47. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997;46(45):1061-6. PMID 9385873C5
  48. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301. doi:10.1136/bmj.k5301 · PMID 30630856C10
  49. Chatterjee NA, Giulianini F, Geelhoed B, Lunetta KL, Misialek JR, Niemeijer MN, et al. Genetic Obesity and the Risk of Atrial Fibrillation: Causal Estimates from Mendelian Randomization. Circulation. 2017;135(8):741-754. doi:10.1161/CIRCULATIONAHA.116.024921 · PMID 27974350H1
  50. Chen D, Zhang J, Wang Y, Jiang W, Xu Y, Xiong C, et al. Risk factors for sternal wound infection after open-heart operations: A systematic review and meta-analysis. Int Wound J. 2024;21(3):e14457. doi:10.1111/iwj.14457 · PMID 37909266C9
  51. Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med. 2014;370(24):2265-75. doi:10.1056/NEJMoa1306187 · PMID 24918371H3
  52. Chávez-Manzanera EA, Vera-Zertuche JM, Kaufer-Horwitz M, Vázquez-Velázquez V, Flores-Lázaro JR, Mireles-Zavala L, et al. Mexican Clinical Practice Guidelines for Adult Overweight and Obesity Management. Curr Obes Rep. 2024;13(4):643-666. doi:10.1007/s13679-024-00585-w · PMID 39356455G1I1
  53. Cinza Sanjurjo S, Prieto Díaz MÁ, Llisterri Caro JL, Barquilla García A, Rodríguez Padial L, Vidal Pérez R, et al. Prevalencia de obesidad y comorbilidad cardiovascular asociada en los pacientes incluidos en el estudio IBERICAN (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal). Semergen. 2019;45(5):311-322. doi:10.1016/j.semerg.2018.11.003 · PMID 30591384G3
  54. Cinza Sanjurjo S, Llisterri Caro JL, Barquilla García A, Polo García J, Velilla Zancada S, Rodríguez Roca GC, et al. Descripción de la muestra, diseño y métodos del estudio para la identificación de la población española de riesgo cardiovascular y renal (IBERICAN). Semergen. 2020;46(1):4-15. doi:10.1016/j.semerg.2019.10.006 · PMID 31870705G3
  55. Cinza-Sanjurjo S, Prieto-Díaz MA, Pallares-Carratala V, Mico-Pérez RM, Barquilla-García A, Velilla-Zancada SM, et al. Prevalence of obesity in primary care patients: The IBERICAN study. Nutr Metab Cardiovasc Dis. 2025;35(5):103751. doi:10.1016/j.numecd.2024.09.021 · PMID 39638674G3
  56. Ciudin A, Baker JL, Belančić A, Busetto L, Dicker D, Fábryová Ľ, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update. Nat Med. 2026;32(6):1962-1966. doi:10.1038/s41591-026-04397-4 · PMID 42120724G1
  57. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970. doi:10.1016/S2213-8587(20)30364-8 · PMID 33137293I1
  58. Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. doi:10.1038/s41591-024-03015-5 · PMID 38796653C5C10
  59. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-8. doi:10.1056/NEJM199708283370901 · PMID 9271479C5
  60. Correction to: 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA): Developed by the task force on the management of cardiovascular disease and chronic kidney disease of the European Society of Cardiology (ESC). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag884 · PMID 42927774G1
  61. Correction to: 2026 ESC Guidelines on cardiac rehabilitation: Developed by the task force on cardiac rehabilitation of the European Society of Cardiology (ESC)Endorsed by the European Society of Physical and Rehabilitation Medicine (ESPRM) and World Organization of Family Doctors (WONCA). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag887 · PMID 42921976G1
  62. Correction to: Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2025;46(9):876. doi:10.1093/eurheartj/ehae915 · PMID 39749997G1
  63. Correia JC, Baker JL, Boyland E, Busetto L, Fábryová L, Helgason T, et al. Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement. Lancet Reg Health Eur. 2026;70:101840. doi:10.1016/j.lanepe.2026.101840 · PMID 42733510G1
  64. Courcoulas A, Abu Dayyeh BK, Eaton L, Robinson J, Woodman G, Fusco M, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427-433. doi:10.1038/ijo.2016.229 · PMID 28017964C9H5
  65. Cremona S, Cohen RV, Pattou F, Casajoana A, Sampaio Souza G, Raverdy V, et al. New Obesity Definition and Clinical Obesity Prevalence for Global Metabolic Bariatric Surgery. JAMA Netw Open. 2026;9(8):e2628395. doi:10.1001/jamanetworkopen.2026.28395 · PMID 42579277G3
  66. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169 · PMID 30312372H5
  67. Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406(10499):149-162. doi:10.1016/S0140-6736(25)01185-7 · PMID 40550231G5
  68. Damman K, Ter Maaten JM, Mayne KJ, Bolignano D, Brown EM, da Costa BR, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag098 · PMID 42661426B4C4C5C10G1I1
  69. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417G2
  70. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-99. doi:10.1001/jama.2015.9676 · PMID 26284720G2
  71. Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659. doi:10.1056/NEJMoa2502082 · PMID 40544432G2G5
  72. Davies MJ, Aroda VR, Bajaj M, ElSayed NA, Giorgino F, Green J, et al. Correction: Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2026. doi:10.1007/s00125-026-06911-2 · PMID 42955083G1
  73. Davies MJ, Aroda VR, Bajaj M, ElSayed NA, Giorgino F, Green J, et al. Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2026. doi:10.1007/s00125-026-06855-7 · PMID 42825923G1
  74. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294C6G1
  75. de Bont J, Díaz Y, Casas M, García-Gil M, Vrijheid M, Duarte-Salles T. Time Trends and Sociodemographic Factors Associated With Overweight and Obesity in Children and Adolescents in Spain. JAMA Netw Open. 2020;3(3):e201171. doi:10.1001/jamanetworkopen.2020.1171 · PMID 32186743G3
  76. de Bont J, Bennett M, León-Muñoz LM, Duarte-Salles T. The prevalence and incidence rate of overweight and obesity among 2.5 million children and adolescents in Spain. Rev Esp Cardiol (Engl Ed). 2022;75(4):300-307. doi:10.1016/j.rec.2021.07.002 · PMID 34384717G3
  77. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3 · PMID 39181597C5
  78. Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257-2268. doi:10.1016/S0140-6736(25)01375-3 · PMID 41138739C4C5
  79. Disse E, Aron-Wisnewsky J, Jacobi D, Clément K, Laville M, Gauthier C, et al. Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data. Diabetes Metab. 2025;51(3):101625. doi:10.1016/j.diabet.2025.101625 · PMID 39971183G3
  80. Docherty KF, Lam CSP, Rakisheva A, Coats AJS, Greenhalgh T, Metra M, et al. Heart failure diagnosis in the general community - Who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2023;25(8):1185-1198. doi:10.1002/ejhf.2946 · PMID 37368511B6
  81. Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022;15(3):321-335. doi:10.1159/000521241 · PMID 35196654H5
  82. Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, et al. Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:: A Population-Based Retrospective Cohort Study. Circulation. 2021;143(15):1468-1480. doi:10.1161/CIRCULATIONAHA.120.052386 · PMID 33813836C9G3
  83. Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. doi:10.1161/ATV.0000000000000153 · PMID 35418240C10
  84. Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356. doi:10.1016/j.soard.2022.08.013 · PMID 36280539C9H5
  85. Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3-14. doi:10.1007/s11695-022-06332-1 · PMID 36336720G1
  86. El-Sheikh M, Bandholm T, Jørgensen NB, Ulrik CS, Barløse M, Møller S, et al. Semaglutide versus diet-based weight loss in obesity and heart failure with reduced ejection fraction (FIT-HF): Protocol for a randomized controlled trial. Clin Nutr ESPEN. 2026;76:105216. doi:10.1016/j.clnesp.2026.105216 · PMID 42988221G5
  87. Ena J, Carretero Gomez J, Sanchez Lora FJ, Bonilla Hernandez MV, Bustos Merlo A, Lobo-Antuña V, et al. Prognostic value of the Edmonton Obesity Staging System among people hospitalized with obesity. Rev Clin Esp (Barc). 2026. doi:10.1016/j.rceng.2026.502619 · PMID 42772598G3
  88. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-90. doi:10.1056/NEJMoa1200303 · PMID 23432189C8
  89. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389 · PMID 29897866C8
  90. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90. N Engl J Med. 2018;378(25):2441-2442. doi:10.1056/NEJMc1806491 · PMID 29897867C8
  91. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031 · PMID 38851997C4C10
  92. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo., European Association for the Study of Obesity (EASO). EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy. J Hepatol. 2026. doi:10.1016/j.jhep.2026.08.028 · PMID 42805503C10
  93. Feijoo L, Rey-Brandariz J, Guerra-Tort C, Candal-Pedreira C, Santiago-Pérez MI, Ruano-Ravina A, et al. Prevalence of obesity in Spain and its autonomous communities, 1987-2020. Rev Esp Cardiol (Engl Ed). 2024;77(10):809-818. doi:10.1016/j.rec.2023.12.018 · PMID 38490640G3H2
  94. Fox CK, Barrientos-Pérez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, et al. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. N Engl J Med. 2025;392(6):555-565. doi:10.1056/NEJMoa2407379 · PMID 39258838G2
  95. Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. Obes Rev. 2005;6(4):275-81. doi:10.1111/j.1467-789X.2005.00199.x · PMID 16246213C9
  96. Félix-Redondo FJ, Grau M, Baena-Díez JM, Dégano IR, de León AC, Guembe MJ, et al. Prevalence of obesity and associated cardiovascular risk: the DARIOS study. BMC Public Health. 2013;13:542. doi:10.1186/1471-2458-13-542 · PMID 23738609G3
  97. Gadiraju S, Lee CJ, Cooper DS. Levothyroxine Dosing Following Bariatric Surgery. Obes Surg. 2016;26(10):2538-42. doi:10.1007/s11695-016-2314-x · PMID 27475799C9
  98. Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336(5):377-388. doi:10.1001/jama.2026.8142 · PMID 42251595G5
  99. García G, Candal-Pedreira C, Guerra-Tort C, Rey-Brandariz J, Teijeiro A, Martin-Gisbert L, et al. Overweight in Spain from 1987 to 2023. Med Clin (Barc). 2026;166(2):107304. doi:10.1016/j.medcli.2025.107304 · PMID 41534394H2
  100. García-Solano M, Gutiérrez-González E, López-Sobaler AM, Ruiz-Álvarez M, Bermejo López LM, Aparicio A, et al. Weight status in the 6- to 9-year-old school population in Spain: results of the ALADINO 2019 Study. Nutr Hosp. 2021;38(5):943-953. doi:10.20960/nh.03618 · PMID 34304573H2
  101. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4 · PMID 36216945G2
  102. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X · PMID 37385275G2
  103. Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081 · PMID 40544433G2G5H5
  104. Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026;14(11):914-926. doi:10.1016/S2213-8587(26)00213-5 · PMID 42810355G5
  105. Gasoyan H, Pfoh ER, Schulte R, Le P, Butsch WS, Rothberg MB. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Netw Open. 2024;7(9):e2433326. doi:10.1001/jamanetworkopen.2024.33326 · PMID 39269703G3
  106. Gasoyan H, Butsch WS, Casacchia NJ, Schulte R, Criswell V, Fox J, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity (Silver Spring). 2025;33(12):2296-2303. doi:10.1002/oby.70058 · PMID 41039650G3
  107. Gasoyan H, Schulte R, Boyer CB, Casacchia NJ, Butsch WS, Le P, et al. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Diabetes Obes Metab. 2026;28(6):4795-4805. doi:10.1111/dom.70660 · PMID 41816857G3
  108. Gessler N, Willems S, Steven D, Aberle J, Akbulak RO, Gosau N, et al. Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial. Europace. 2021;23(10):1548-1558. doi:10.1093/europace/euab122 · PMID 33895833C4C9H1
  109. Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. doi:10.1111/dom.70209 · PMID 41090431G5
  110. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis. Eur Heart J Cardiovasc Pharmacother. 2024;10(7):614-645. doi:10.1093/ehjcvp/pvae064 · PMID 39237457C3C9
  111. Gilbert O, Gulati M, Gluckman TJ, Kittleson MM, Rikhi R, Saseen JJ, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(7):536-555. doi:10.1016/j.jacc.2025.05.024 · PMID 40539956G1
  112. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119-33. doi:10.1111/j.1365-2125.2004.02157.x · PMID 15255794B3C3
  113. Green DJ, Haynes A, Underwood DR, Winterton ER, Green AA, Daly RM, et al. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial. Nat Med. 2026. doi:10.1038/s41591-026-04752-5 · PMID 43003902G5
  114. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4 · PMID 20673995C4G2
  115. Grunstein RR, Somers VK, Azarbarzin A, Malhotra A, Sands SA, Lucey BP, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. 2026. doi:10.1056/NEJMoa2611477 · PMID 42904878G5
  116. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985;27(2-3):160-71. PMID 3928246C5
  117. Gutiérrez-Fisac JL, Guallar-Castillón P, León-Muñoz LM, Graciani A, Banegas JR, Rodríguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes Rev. 2012;13(4):388-92. doi:10.1111/j.1467-789X.2011.00964.x · PMID 22151906G3H2
  118. Gutiérrez-Fisac JL, León-Muñoz LM, Regidor E, Banegas J, Rodríguez-Artalejo F. Trends in obesity and abdominal obesity in the older adult population of Spain (2000-2010). Obes Facts. 2013;6(1):1-8. doi:10.1159/000348493 · PMID 23428930G3
  119. Gutiérrez-González E, García-Solano M, Pastor-Barriuso R, Fernández de Larrea-Baz N, Rollán-Gordo A, Peñalver-Argüeso B, et al. Socio-geographical disparities of obesity and excess weight in adults in Spain: insights from the ENE-COVID study. Front Public Health. 2023;11:1195249. doi:10.3389/fpubh.2023.1195249 · PMID 37529423H2
  120. Haddy N, Jourdain H, Desplas D, Bertrand M, Jabagi MJ, Rives-Lange C, et al. Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study. BioDrugs. 2025;39(2):321-332. doi:10.1007/s40259-024-00699-6 · PMID 39930059G3
  121. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006. doi:10.1161/CIRCRESAHA.116.305697 · PMID 25767285H1
  122. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C9G1
  123. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211. doi:10.7326/0003-4819-143-3-200508020-00006 · PMID 16061918H3
  124. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859-868. doi:10.1016/S2213-8587(22)00277-7 · PMID 36356613I1
  125. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000 · PMID 38324483C10
  126. Hasan B, Nayfeh T, Alzuabi M, Wang Z, Kuchkuntla AR, Prokop LJ, et al. Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(12). doi:10.1210/clinem/dgaa673 · PMID 32954416H1
  127. Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296 · PMID 38958939G3
  128. He K, Wei Y, Zhao H, Zhang L, Wu F, Liu R, et al. Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist. Diabetes Obes Metab. 2026;28(12):11643-11652. doi:10.1111/dom.71218 · PMID 42764407G5
  129. Hernáez Á, Zomeño MD, Dégano IR, Pérez-Fernández S, Goday A, Vila J, et al. Excess Weight in Spain: Current Situation, Projections for 2030, and Estimated Direct Extra Cost for the Spanish Health System. Rev Esp Cardiol (Engl Ed). 2019;72(11):916-924. doi:10.1016/j.rec.2018.10.010 · PMID 30473259H2
  130. Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32(3):869-882. doi:10.1038/s41591-026-04204-0 · PMID 41772149G5
  131. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl 2(Suppl 2):S101-6. doi:10.2337/dc11-s202 · PMID 21525438H5
  132. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-9. doi:10.2337/dc13-0234 · PMID 24144653G2
  133. Hookana E, Junttila MJ, Puurunen VP, Tikkanen JT, Kaikkonen KS, Kortelainen ML, et al. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 2011;8(10):1570-5. doi:10.1016/j.hrthm.2011.06.031 · PMID 21740887H1
  134. Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. doi:10.1016/S0140-6736(26)00656-2 · PMID 42119587G5
  135. Horn DB, Linetzky B, Davies MJ, Laffin LJ, Wang H, Murphy MA, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157-167. doi:10.1001/jamainternmed.2025.6112 · PMID 41284285G5
  136. Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927-2944. doi:10.1016/S0140-6736(25)02165-8 · PMID 41275875G2G5
  137. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med. 2018;379(7):623-632. doi:10.1056/NEJMoa1803626 · PMID 30110591C8
  138. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009;22(12):1311-9; quiz 1417-8. doi:10.1016/j.echo.2009.10.013 · PMID 19944955H5
  139. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593-606. doi:10.1038/s41569-022-00679-9 · PMID 35296869H1H5
  140. Iturralde-Iriso J, Lertxundi-Manterola A, Delgado-Naranjo I, Barquilla-García A, Micó-Pérez RM, Polo-García J, et al. Estimation of the population atributable fraction due a to excess body fat in primary care patients: IBERICAN study. Prim Care Diabetes. 2025;19(3):302-311. doi:10.1016/j.pcd.2025.02.009 · PMID 40113502G3
  141. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjöström L, Karason K. Bariatric Surgery and the Risk of New-Onset Atrial Fibrillation in Swedish Obese Subjects. J Am Coll Cardiol. 2016;68(23):2497-2504. doi:10.1016/j.jacc.2016.09.940 · PMID 27931605C9
  142. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-17. doi:10.1056/NEJMoa1003114 · PMID 20818901C5G2
  143. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65. doi:10.2165/00003088-200544100-00004 · PMID 16176118B3C3
  144. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 · PMID 35658024C4C7G2H5I1
  145. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972 · PMID 37366315G5H5
  146. Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. doi:10.1056/NEJMoa2504214 · PMID 40549887G5
  147. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819 · PMID 39536238C7G2I1
  148. Jastreboff AM, Harder-Lauridsen NM, Van Name M, Körner A, Kelly AS, Weghuber D, et al. Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age. N Engl J Med. 2026. doi:10.1056/NEJMoa2604058 · PMID 43037562G5
  149. Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026;395(18):1781-1793. doi:10.1056/NEJMoa2604169 · PMID 42814954C7G2G5
  150. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69(7):841-858. doi:10.1016/j.jacc.2016.11.069 · PMID 28209226H1
  151. Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(9):777-789. doi:10.1016/S2213-8587(25)00141-X · PMID 40555243G5
  152. Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. doi:10.1056/NEJMoa2411528 · PMID 40421736G5
  153. Jiménez A, Ibarzabal A, Moizé V, Pané A, Andreu A, Molero J, et al. Ten-year outcomes after Roux-en-Y gastric bypass and sleeve gastrectomy: an observational nonrandomized cohort study. Surg Obes Relat Dis. 2019;15(3):382-388. doi:10.1016/j.soard.2019.01.020 · PMID 30772254G3
  154. Johansen MØ, Nielsen SF, Afzal S, Vedel-Krogh S, Davey Smith G, Nordestgaard BG. Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study. Clin Chem. 2021;67(1):276-287. doi:10.1093/clinchem/hvaa290 · PMID 33409531H1
  155. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69-77. doi:10.1002/ejhf.657 · PMID 27790809I1
  156. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206. doi:10.1016/S2213-8587(22)00008-0 · PMID 35131037G2
  157. Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948-2958. doi:10.1038/s41591-026-04479-3 · PMID 42252333G2
  158. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. doi:10.5664/jcsm.6506 · PMID 28162150H3
  159. Karch SB, Mari F, Bartolini V, Bertol E. Aminorex poisoning in cocaine abusers. Int J Cardiol. 2012;158(3):344-6. doi:10.1016/j.ijcard.2011.06.105 · PMID 21764154C5
  160. Karlström P, Pivodic A, Fu M. Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients. JACC Heart Fail. 2025;13(5):754-766. doi:10.1016/j.jchf.2024.12.004 · PMID 40088230G3
  161. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128. doi:10.1056/NEJMoa1916038 · PMID 32233338G2G5
  162. Kelly AS, Pamidipati KC, Rachmiel M, Srivastava G, Hsia DS, Fox CK, et al. Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.23420 · PMID 43035096G2G5
  163. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305-13. doi:10.1056/NEJMoa020245 · PMID 12151467H1
  164. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 · PMID 37947085C8H4
  165. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018 · PMID 38490803C10G1
  166. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2025;39(1):180-183. doi:10.1007/s00464-024-11263-2 · PMID 39370500C9I1
  167. Kittleson MM, Benjamin EJ, Blumer V, Harrington J, Januzzi JL, McMurray JJV, et al. 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025;86(20):1953-1975. doi:10.1016/j.jacc.2025.05.008 · PMID 40512113G1
  168. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;315(1):36-46. doi:10.1001/jama.2015.17346 · PMID 26746456H1
  169. Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026;408(10564):1557-1570. doi:10.1016/S0140-6736(26)01865-9 · PMID 42815506C7G5
  170. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. doi:10.1016/S0140-6736(23)01185-6 · PMID 37385278G2
  171. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512 · PMID 11832527H3
  172. Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020;8(8):657-666. doi:10.1016/j.jchf.2020.04.016 · PMID 32653449H1
  173. Konieczna J, Ruiz-Canela M, Galmes-Panades AM, Abete I, Babio N, Fiol M, et al. An Energy-Reduced Mediterranean Diet, Physical Activity, and Body Composition: An Interim Subgroup Analysis of the PREDIMED-Plus Randomized Clinical Trial. JAMA Netw Open. 2023;6(10):e2337994. doi:10.1001/jamanetworkopen.2023.37994 · PMID 37851444C8
  174. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 · PMID 37622681C4C5C6C7G2H1I1
  175. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. doi:10.1016/S0140-6736(24)01643-X · PMID 39222642C5I1
  176. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394-1407. doi:10.1056/NEJMoa2313917 · PMID 38587233C4C5C6C7G2I1
  177. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024;45(38):4063-4098. doi:10.1093/eurheartj/ehae508 · PMID 39210706B4B6C3C4C5C6C7C8C9C10D1D4G1G5H1H3H4H5I1
  178. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2025;32(3):184-220. doi:10.1093/eurjpc/zwae279 · PMID 39210708G1
  179. Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol. 1998;51(4):361-4. doi:10.1016/s0895-4356(97)00289-8 · PMID 9539893C5
  180. Krüger N, Schneeweiss S, Fuse K, Matseyko S, Sreedhara SK, Hahn G, et al. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2025;334(14):1255-1266. doi:10.1001/jama.2025.14092 · PMID 40886075G3
  181. Kumbhani DJ, Armbruster AL, Cheng RK, Chrispin J, Fischer U, Holbrook AM, et al. Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026;88(11):1255-1283. doi:10.1016/j.jacc.2026.05.033 · PMID 42377292C3
  182. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420B1B6C2C3C4C5C6C7C9D1E3G1H1H5I1
  183. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293-302. doi:10.1038/nrendo.2014.29 · PMID 24663222H5
  184. Laddu D, Neeland IJ, Carnethon M, Stanford FC, Mongraw-Chaffin M, Barone Gibbs B, et al. Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association. Circulation. 2024;150(1):e7-e19. doi:10.1161/CIR.0000000000001221 · PMID 38766861G1
  185. Lam CSP, Rodriguez A, Aminian A, Ferrannini E, Heerspink HJL, Jastreboff AM, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring). 2025;33(9):1645-1656. doi:10.1002/oby.24332 · PMID 40545827C5G2G5I1
  186. Lamperti M, Romero CS, Guarracino F, Cammarota G, Vetrugno L, Tufegdzic B, et al. Preoperative assessment of adults undergoing elective noncardiac surgery: Updated guidelines from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2025;42(1):1-35. doi:10.1097/EJA.0000000000002069 · PMID 39492705C9E3I1I2
  187. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-8. doi:10.1056/NEJMsr1606602 · PMID 27557308H3
  188. Lazarus JV, Ortiz A, Tyrovolas S, Fernández E, Guy D, White TM, et al. A GBD 2019 study of health and Sustainable Development Goal gains and forecasts to 2030 in Spain. Sci Rep. 2022;12(1):21154. doi:10.1038/s41598-022-24719-z · PMID 36477107H2
  189. Lazzati A, Audureau E, Hemery F, Schneck AS, Gugenheim J, Azoulay D, et al. Reduction in early mortality outcomes after bariatric surgery in France between 2007 and 2012: A nationwide study of 133,000 obese patients. Surgery. 2016;159(2):467-74. doi:10.1016/j.surg.2015.08.005 · PMID 26376758G3
  190. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409. doi:10.1016/S0140-6736(17)30069-7 · PMID 28237263G2I1
  191. le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026;395(8):776-787. doi:10.1056/NEJMoa2600751 · PMID 42253238G2G5
  192. Lecube A, de Hollanda A, Calañas A, Vilarrasa N, Rubio MA, Breton I, et al. Trends in Bariatric Surgery in Spain in the Twenty-First Century: Baseline Results and 1-Month Follow Up of the RICIBA, a National Registry. Obes Surg. 2016;26(8):1836-42. doi:10.1007/s11695-015-2001-3 · PMID 26661106G3
  193. Lecube A, Lecube A, Azriel S, Barreiro E, Blay G, Carretero-Gómez J, et al. The Spanish GIRO Guideline: A Paradigm Shift in the Management of Obesity in Adults. Obes Facts. 2025;18(4):375-387. doi:10.1159/000544880 · PMID 40159422B4B6C7D1G1
  194. Li S, Zheng Y, Huang Y, He W, Liu X, Zhu W. Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis. Int J Cardiol. 2022;361:40-46. doi:10.1016/j.ijcard.2022.05.018 · PMID 35568057H1
  195. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3(3):CD007506. doi:10.1002/14651858.CD007506.pub4 · PMID 30921477H3
  196. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 · PMID 37952131C4C5C6C7C10D1G2G5H1H5I1
  197. Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948. doi:10.1016/S2213-8587(25)00225-6 · PMID 40961953G2G5
  198. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54. doi:10.1056/NEJMoa1212914 · PMID 23796131C4C8G2H1
  199. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801-9. doi:10.1016/S2213-8587(14)70156-1 · PMID 25127483C10
  200. Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913-921. doi:10.1016/S2213-8587(16)30162-0 · PMID 27595918C4C7C8
  201. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275 · PMID 39996356G5
  202. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. doi:10.1056/NEJMoa2401943 · PMID 38856224C10I1
  203. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-9. doi:10.1001/archgenpsychiatry.2010.2 · PMID 20194822H3
  204. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 · PMID 31504418B4C8D1G1H1H3
  205. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190 · PMID 40878289G1H4
  206. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30(7):850-6. doi:10.1093/eurheartj/ehn573 · PMID 19136488H1
  207. Mailhac A, Pedersen L, Pottegård A, Søndergaard J, Mogensen T, Sørensen HT, et al. Semaglutide (Ozempic(®)) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss. Clin Epidemiol. 2024;16:307-318. doi:10.2147/CLEP.S456170 · PMID 38685990G3
  208. Mailhac A, Pedersen L, Petersen I, Pottegård A, Sørensen HT, Thomsen RW. Discontinuation of Semaglutide Therapy for Obesity Management. JAMA Netw Open. 2026;9(8):e2631371. doi:10.1001/jamanetworkopen.2026.31371 · PMID 42664011G3
  209. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881 · PMID 38912654C4G2H1H3I1
  210. Malhotra A, Gottlieb DJ, Woehrle H, Dennehy EB, Calamai G, Liu Z, et al. Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. 2026. doi:10.1001/jama.2026.24080 · PMID 43002161G5
  211. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;316(5):500-8. doi:10.1001/jama.2016.10260 · PMID 27483064I1
  212. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi:10.1056/NEJMoa1603827 · PMID 27295427C5I1
  213. Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874-1882. doi:10.1111/jth.15358 · PMID 34259389C3C9
  214. Martín-Ramiro JJ, Álvarez-Martín E, Gil-Prieto R. Mortalidad atribuible al exceso de peso en España. Med Clin (Barc). 2014;142(12):526-30. doi:10.1016/j.medcli.2013.04.047 · PMID 24183117H2
  215. Martínez-González MA, Buil-Cosiales P, Corella D, Bulló M, Fitó M, Vioque J, et al. Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. Int J Epidemiol. 2019;48(2):387-388o. doi:10.1093/ije/dyy225 · PMID 30476123C8
  216. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192 · PMID 37622663B4B6C2C4C9D1G1H3H5
  217. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. doi:10.1093/eurheartj/ehae179 · PMID 39210722C6G1
  218. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178 · PMID 39210715B1B4B6C4C6C8D1E3G1H1H3H4H5
  219. McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31(10):3317-3329. doi:10.1038/s41591-025-03978-z · PMID 41039116G1
  220. McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229-3232. doi:10.1038/s41591-025-03765-w · PMID 41039115G1
  221. McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006 · PMID 40162642C7
  222. Mediano O, González Mangado N, Montserrat JM, Alonso-Álvarez ML, Almendros I, Alonso-Fernández A, et al. International Consensus Document on Obstructive Sleep Apnea. Arch Bronconeumol. 2022;58(1):52-68. doi:10.1016/j.arbres.2021.03.017 · PMID 33875282H3
  223. Mentias A, Aminian A, Youssef D, Pandey A, Menon V, Cho L, et al. Long-Term Cardiovascular Outcomes After Bariatric Surgery in the Medicare Population. J Am Coll Cardiol. 2022;79(15):1429-1437. doi:10.1016/j.jacc.2022.01.047 · PMID 35422238G3
  224. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263-73. doi:10.1001/jama.2013.277669 · PMID 24065013H3
  225. Meyhöfer SM, Cariou B, Cercato C, Colhoun HM, Deanfield J, Long MT, et al. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nat Med. 2026;32(5):1686-1693. doi:10.1038/s41591-026-04281-1 · PMID 41928037C10
  226. Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026;395(2):138-150. doi:10.1056/NEJMoa2512275 · PMID 42418774I1
  227. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Capristo E, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293-304. doi:10.1016/S0140-6736(20)32649-0 · PMID 33485454C9
  228. Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, Murphy PB, Piper AJ, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(3):e6-e24. doi:10.1164/rccm.201905-1071ST · PMID 31368798H3H5
  229. Monzo L, Savarese G, Mullens W, Abdin A, Bozkurt B, Chioncel O, et al. Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document. Eur J Heart Fail. 2025;27(11):2465-2479. doi:10.1002/ejhf.70082 · PMID 41309245G1
  230. Mora P, Aroda VR, Asong M, Blüher M, Heftdal LD, Carlander AF, et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026;408(10555):621-635. doi:10.1016/S0140-6736(26)01248-1 · PMID 42532080G5
  231. Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K, et al. Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. Lancet. 2026. doi:10.1016/S0140-6736(26)01953-7 · PMID 43014326G5
  232. Moussa O, Ardissino M, Heaton T, Tang A, Khan O, Ziprin P, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J. 2020;41(28):2660-2667. doi:10.1093/eurheartj/ehaa069 · PMID 32188981G3
  233. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-731. doi:10.1002/ejhf.1494 · PMID 31222929H1
  234. Nadolsky K, Garvey WT, Agarwal M, Bonnecaze A, Burguera B, Chaplin MD, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update. Endocr Pract. 2025;31(11):1351-1394. doi:10.1016/j.eprac.2025.07.017 · PMID 40956256G1
  235. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. doi:10.1161/CIR.0000000000001184 · PMID 37807924H3H5
  236. Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, Bajaj M, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(22S):e1889-e2007. doi:10.1016/j.jacc.2026.03.056 · PMID 42265997B4B6C4C5C7C10G1H4H5I1
  237. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-725. doi:10.1016/S2213-8587(19)30084-1 · PMID 31301983H1H5
  238. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376-82. doi:10.1038/ajg.2012.466 · PMID 23358462H3
  239. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394 · PMID 30165437G1
  240. Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928 · PMID 41406444C5I1
  241. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016;315(10):990-1004. doi:10.1001/jama.2016.1558 · PMID 26954408C5G2
  242. Näslund E, Stenberg E, Hofmann R, Ottosson J, Sundbom M, Marsk R, et al. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Severe Obesity: A Nationwide Cohort Study. Circulation. 2021;143(15):1458-1467. doi:10.1161/CIRCULATIONAHA.120.048585 · PMID 33103469G3
  243. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. doi:10.1161/CIRCULATIONAHA.116.026807 · PMID 28381470H1
  244. Orozco-Beltrán D, Brotons-Cuixart C, Banegas JR, Gil-Guillen VF, Cebrián-Cuenca AM, Martín-Rioboó E, et al. Recomendaciones preventivas vasculares. Actualización PAPPS 2024. Aten Primaria. 2024;56 Suppl 1(Suppl 1):103123. doi:10.1016/j.aprim.2024.103123 · PMID 39613355D4
  245. Ostrominski JW, Plutzky J, Scirica BM, Hovingh GK, Jeppesen OK, Lincoff AM, et al. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial. JAMA Cardiol. 2026;11(11):1103-1112. doi:10.1001/jamacardio.2026.3566 · PMID 42747817C5
  246. Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol. 2018;71(20):2360-2372. doi:10.1016/j.jacc.2018.03.509 · PMID 29773163H1
  247. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 · PMID 39555826C4C5C6C7G2G5H1I1
  248. Pan A, Yang S, Ramos R, Li X, Xie J, Eckel RH, et al. Validation of clinical and preclinical obesity across global cohorts. Nature. 2026. doi:10.1038/s41586-026-11237-5 · PMID 43015459H2
  249. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017;13(5):727-741. doi:10.1016/j.soard.2016.12.018 · PMID 28392254B4
  250. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159-69. doi:10.1016/j.jacc.2015.03.002 · PMID 25792361C4C7C9H1
  251. Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Litwin S, Zile M, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J. 2025;46(25):2372-2390. doi:10.1093/eurheartj/ehaf057 · PMID 39873282C7
  252. Peled Y, Ducharme A, Kittleson M, Bansal N, Stehlik J, Amdani S, et al. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. J Heart Lung Transplant. 2024;43(10):1529-1628.e54. doi:10.1016/j.healun.2024.05.010 · PMID 39115488C6
  253. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. doi:10.1093/eurheartj/ehaa605 · PMID 32860412B4C4C8D1G1
  254. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. doi:10.1001/jama.284.23.3015 · PMID 11122588C4H1H3
  255. Pereira JPS, Calafatti M, Martinino A, Ramnarain D, Stier C, Parmar C, et al. Epicardial Adipose Tissue Changes After Bariatric and Metabolic Surgery: a Systematic Review and Meta-analysis. Obes Surg. 2023;33(11):3636-3648. doi:10.1007/s11695-023-06848-0 · PMID 37801237H1
  256. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347 · PMID 38785209C10
  257. Peterli R, Wölnerhanssen BK, Peters T, Vetter D, Kröll D, Borbély Y, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA. 2018;319(3):255-265. doi:10.1001/jama.2017.20897 · PMID 29340679G2
  258. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 · PMID 26132939C4C7G2I1
  259. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi:10.1161/CIR.0000000000000973 · PMID 33882682G1
  260. Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026;32(7):2673-2678. doi:10.1038/s41591-026-04440-4 · PMID 42260100G5
  261. Pérez-Rodrigo C, Gianzo Citores M, Hervás Bárbara G, Aranceta-Bartrina J. Prevalence of obesity and abdominal obesity in Spanish population aged 65 years and over: ENPE study. Med Clin (Barc). 2022;158(2):49-57. doi:10.1016/j.medcli.2020.10.025 · PMID 33509603G3
  262. Qaseem A, Cross JT Jr, Harrod CS, Owens DK, Balk EM, Crandall CJ, et al. Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). Ann Intern Med. 2026;179(8):1177-1185. doi:10.7326/ANNALS-25-02714 · PMID 42296496G1
  263. Reddy YNV, Anantha-Narayanan M, Obokata M, Koepp KE, Erwin P, Carter RE, et al. Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2019;7(8):678-687. doi:10.1016/j.jchf.2019.04.019 · PMID 31302042H1
  264. Redondo-Antón J, Pérez-Martínez P, Cuatrecasas G, Rubio-de Santos M, Díaz-Cerezo S. Nationwide real-world assessment of the economic impact of obesity in Spanish healthcare settings (ECC-OS). Semergen. 2026;52(1):102662. doi:10.1016/j.semerg.2025.102662 · PMID 41512590G3H2
  265. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520 · PMID 37363821H5
  266. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003 · PMID 37364790C10
  267. Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672-1686f. doi:10.1093/eurheartj/ehy066 · PMID 29509886C3
  268. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. doi:10.1001/jamainternmed.2024.2525 · PMID 38976257G3
  269. Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349 · PMID 39888616G3
  270. Romeo S, Vidal-Puig A, Husain M, Ahima R, Arca M, Bhatt DL, et al. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Eur Heart J. 2025;46(38):3685-3713. doi:10.1093/eurheartj/ehaf314 · PMID 40331343G1
  271. Romero-Gómez M, Escalada J, Noguerol M, Pérez A, Carretero J, Crespo J, et al. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis. Gastroenterol Hepatol. 2025;48(8):502442. doi:10.1016/j.gastrohep.2025.502442 · PMID 40221023C10
  272. Rosenstock J, Lingvay I, Ryan D, Jastreboff AM, Kushner R, Acosta A, et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2026;32(8):2941-2947. doi:10.1038/s41591-026-04476-6 · PMID 42249138G5
  273. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224 · PMID 33755728C4C7G2I1
  274. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619 · PMID 35015037G2I1
  275. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4 · PMID 39824205B4B7C4C6C7C8C10D1D4E3G1G5H1H3H4H5
  276. Ruiz-Canela M, Corella D, Martínez-González MÁ, Babio N, Martínez JA, Forga L, et al. Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes : A Secondary Analysis of a Randomized Controlled Trial. Ann Intern Med. 2025;178(10):1378-1389. doi:10.7326/ANNALS-25-00388 · PMID 40854218C8
  277. Ruiz-García A, Arranz-Martínez E, Morales-Cobos LE, García-Álvarez JC, Iturmendi-Martínez N, Rivera-Teijido M, et al. Prevalence rates of overweight and obesity and their associations with cardiometabolic and renal factors. SIMETAP-OB study. Clin Investig Arterioscler. 2022;34(6):291-302. doi:10.1016/j.arteri.2022.03.006 · PMID 35618556G3
  278. Ruiz-García A, Serrano-Cumplido A, Escobar-Cervantes C, Arranz-Martínez E, Pallarés-Carratalá V. Prevalence Rates of Abdominal Obesity, High Waist-to-Height Ratio and Excess Adiposity, and Their Associated Cardio-Kidney-Metabolic Factors: SIMETAP-AO Study. Nutrients. 2024;16(22). doi:10.3390/nu16223948 · PMID 39599733G3
  279. Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049-2057. doi:10.1038/s41591-024-02996-7 · PMID 38740993C5
  280. Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, et al. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Diabetes Care. 2019;42(5):777-788. doi:10.2337/dc18-0836 · PMID 30389673C8
  281. Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA. 2018;319(3):241-254. doi:10.1001/jama.2017.20313 · PMID 29340676G2
  282. Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258 · PMID 40305708C4C10G2
  283. Savarese G, Schiattarella GG, Lindberg F, Anker MS, Bayes-Genis A, Bäck M, et al. Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2025;27(7):1273-1293. doi:10.1002/ejhf.3676 · PMID 40328668G1
  284. Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701-709. doi:10.1016/j.jchf.2018.05.018 · PMID 30007554H1
  285. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-76. doi:10.1056/NEJMoa1200225 · PMID 22449319G2
  286. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869 · PMID 28199805C9G2
  287. Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132-1142. doi:10.1161/CIRCULATIONAHA.117.032130 · PMID 29133606C9
  288. Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, Pedersen SD, Chen K, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. N Engl J Med. 2026. doi:10.1056/NEJMoa2610676 · PMID 43001755G5
  289. Schröder H, Juton C, Goran MI, Wärnberg J, Osés M, Gonzalez-Gross M, et al. Twenty-year trend in the prevalence of increased cardiometabolic risk, measured by abdominal obesity, among Spanish children and adolescents across body mass index categories. BMC Med. 2024;22(1):509. doi:10.1186/s12916-024-03719-y · PMID 39501283G3
  290. Scirica BM, Lincoff AM, Lingvay I, Bogdanski P, Buscemi S, Colhoun H, et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. J Am Coll Cardiol. 2024;84(17):1632-1642. doi:10.1016/j.jacc.2024.08.007 · PMID 39217559C5
  291. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-2454. doi:10.1093/eurheartj/ehab309 · PMID 34120177C8
  292. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-2467. doi:10.1093/eurheartj/ehab312 · PMID 34120185C8
  293. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, et al. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. 2020;141(10):843-862. doi:10.1161/CIRCULATIONAHA.119.041022 · PMID 31992065H5
  294. Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383(11):1000-1002. doi:10.1056/NEJMp2003873 · PMID 32905671G2
  295. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-52. doi:10.1056/NEJMoa066254 · PMID 17715408C9G2
  296. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-62. doi:10.1016/S1470-2045(09)70159-7 · PMID 19556163H3
  297. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65. doi:10.1001/jama.2011.1914 · PMID 22215166C9G2H1
  298. Sorimachi H, Obokata M, Omote K, Reddy YNV, Takahashi N, Koepp KE, et al. Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery. J Am Coll Cardiol. 2022;80(16):1501-1512. doi:10.1016/j.jacc.2022.08.738 · PMID 36229085H1
  299. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065 · PMID 33895845C3
  300. Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-90. doi:10.1056/NEJMoa0806375 · PMID 19179316H3
  301. Sundström J, Bruze G, Ottosson J, Marcus C, Näslund I, Neovius M. Weight Loss and Heart Failure: A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment. Circulation. 2017;135(17):1577-1585. doi:10.1161/CIRCULATIONAHA.116.025629 · PMID 28258170G3
  302. Swift DL, Ross LM, Laddu DR, Conroy MB, German CA, Evangelista LS, et al. Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2026;154(1):e1-e16. doi:10.1161/CIR.0000000000001441 · PMID 42220241G1
  303. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. doi:10.1152/physrev.00033.2011 · PMID 23303913H1H5
  304. Testelmans D, Schwarz EI, Anttalainen U, Basoglu ÖK, Bradicich M, Craig S, et al. ERS/ESRS clinical practice guideline for continuous positive airway pressure for the treatment of adult obstructive sleep apnoea. Eur Respir J. 2026. doi:10.1183/13993003.01186-2026 · PMID 42860272H3
  305. Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D, et al. Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol. 2019;7(10):786-795. doi:10.1016/S2213-8587(19)30191-3 · PMID 31383618G3
  306. Thompson A, Fleischmann KE, Smilowitz NR, de Las Fuentes L, Mukherjee D, Aggarwal NR, et al. 2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;88(13):1543-1643. doi:10.1016/j.jacc.2026.06.017 · PMID 42813718C9
  307. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376(9740):517-23. doi:10.1016/S0140-6736(10)60935-X · PMID 20709233C5G2
  308. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-61. doi:10.2337/diacare.27.1.155 · PMID 14693982C5G2I1
  309. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008;29(18):2227-33. doi:10.1093/eurheartj/ehn324 · PMID 18611964H1
  310. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-50. doi:10.1056/NEJM200105033441801 · PMID 11333990H3
  311. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463-474. doi:10.1038/s41569-023-00849-3 · PMID 36977782H5
  312. Valdés S, García-Torres F, Maldonado-Araque C, Goday A, Calle-Pascual A, Soriguer F, et al. Prevalence of obesity, diabetes and other cardiovascular risk factors in Andalusia (southern Spain). Comparison with national prevalence data. The Di@bet.es study. Rev Esp Cardiol (Engl Ed). 2014;67(6):442-8. doi:10.1016/j.rec.2013.09.029 · PMID 24863592G3
  313. Valenzuela PL, Santos-Lozano A, Saco-Ledo G, Castillo-García A, Lucia A. Obesity, cardiovascular risk, and lifestyle: cross-sectional and prospective analyses in a nationwide Spanish cohort. Eur J Prev Cardiol. 2023;30(14):1493-1501. doi:10.1093/eurjpc/zwad204 · PMID 37317985G3
  314. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176 · PMID 39210723B1B4B6C2C4C6C7C9D1E3G1H1H3H5
  315. van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955-1969. doi:10.1093/eurheartj/ehac071 · PMID 35243488C9
  316. Vergniory-Trueba O, Treceño-Lobato C. Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study. Healthcare (Basel). 2026;14(19). doi:10.3390/healthcare14193355 · PMID 42881794G3
  317. Verrastro O, Panunzi S, Castagneto-Gissey L, De Gaetano A, Lembo E, Capristo E, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786-1797. doi:10.1016/S0140-6736(23)00634-7 · PMID 37088093C10
  318. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484 · PMID 34458905B4B6C2C4C6C8C9D1E3G1H1H3H4H5I1
  319. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177 · PMID 39210710B1B6C2C3C4C5C6C8D1E3G1H1H4H5I1
  320. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-20. doi:10.1038/oby.2010.147 · PMID 20559296G2
  321. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-51. doi:10.1038/ijo.2013.120 · PMID 23812094G2I1
  322. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831 · PMID 33625476G2
  323. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. doi:10.1038/s41591-023-02597-w · PMID 37840095G2
  324. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292(20):2471-7. doi:10.1001/jama.292.20.2471 · PMID 15562125H1
  325. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. doi:10.1038/s41591-023-02672-2 · PMID 38182782G3
  326. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601 · PMID 36322838G2
  327. Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774 · PMID 40960239C7G2G5
  328. Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8 · PMID 40961952G2G5I1
  329. Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969 · PMID 40934115C4C7G2G5I1
  330. Wharton S, Broholm C, Horn D, Pinta AR, Rubino D, Broholm ZR, et al. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. Lancet Diabetes Endocrinol. 2026. doi:10.1016/S2213-8587(26)00275-5 · PMID 43033821G5
  331. Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. 2026. doi:10.1056/NEJMoa2607219 · PMID 42820639G2G5
  332. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 · PMID 33567185C4C7G2H5I1
  333. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725 · PMID 35441470C4C7G2G5I1
  334. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-6. doi:10.2337/dc10-2415 · PMID 21593294C4H1H3
  335. Winter E, Wolff Sagy Y, Reges O, Feldhamer I, Abu Ahmad W, Arbel R, et al. Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study. Diabetes Obes Metab. 2026. doi:10.1111/dom.71488 · PMID 42957437G3
  336. Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745-51. doi:10.1016/j.jacc.2010.11.045 · PMID 21511110H1
  337. Writing Committee Members, Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154(4):e50-e158. doi:10.1161/CIR.0000000000001453 · PMID 42263157G1
  338. Yazdany T, Jakus-Waldman S, Jeppson PC, Schimpf MO, Yurteri-Kaplan LA, Ferzandi TR, et al. American Urogynecologic Society Systematic Review: The Impact of Weight Loss Intervention on Lower Urinary Tract Symptoms and Urinary Incontinence in Overweight and Obese Women. Female Pelvic Med Reconstr Surg. 2020;26(1):16-29. doi:10.1097/SPV.0000000000000802 · PMID 31860569H3
  339. Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;144(3):e56-e67. doi:10.1161/CIR.0000000000000988 · PMID 34148375H1H3H5
  340. Yevusiak T, Weisman A, Retnakaran R, Wharton S, Drucker DJ, Kramer CK. Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol. PLoS One. 2026;21(7):e0354237. doi:10.1371/journal.pone.0354237 · PMID 42507673G5
  341. Yokote K, Yamauchi T, Shingaki T, Chin R, Oura T, Nagai Y, et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2026. doi:10.1016/S2213-8587(26)00232-9 · PMID 42962687G5
  342. Yska JP, Arfman IJ, van Oijen MA, de Heide LJM, Emous M, Veeger NJGM, et al. Long-term Effect of Bariatric Surgery on the Use of Levothyroxine and Thyroid Levels. Obes Surg. 2022;32(3):742-748. doi:10.1007/s11695-021-05810-2 · PMID 34855136C9

Otros documentos con DOI (3)

  1. Carrillo Fernández L, Sagredo Pérez J, Guede Fernández C, Sanz Vela N. Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS. Diabetes práctica. 2026. doi:10.52102/diabet/pract.2025.2.art3G1
  2. Castro Conde A, Gorgojo Martínez JJ, Górriz Teruel JL, Manito Lorite N, Cobo Marcos M, Freixa-Pamias R, et al. Obesidad y enfermedad cardiovascular y renal. Posicionamiento de las Asociaciones de Cardiología Preventiva, Cardiología Clínica e Insuficiencia Cardiaca de la SEC. REC: CardioClinics. 2024;59(3):212-224. doi:10.1016/j.rccl.2024.04.003G1
  3. Castro Conde A, Gorgojo Martínez JJ, Manito Lorite N. Actualización del posicionamiento sobre obesidad y enfermedad cardiovascular y renal de las Asociaciones de Cardiología Preventiva, Cardiología Clínica e Insuficiencia Cardiaca de la SEC. REC: CardioClinics. 2025;60(2):158-160. doi:10.1016/j.rccl.2024.11.004G1

Fichas técnicas (CIMA, AEMPS) (52)

  1. Ficha técnica de acenocumarol (4 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 25670C3
  2. Ficha técnica de alteplasa. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 59494C3
  3. Ficha técnica de amiodarona (150 mg/3 mL, solución inyectable). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 54723C3
  4. Ficha técnica de amiodarona (200 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 48048C3
  5. Ficha técnica de apixabán (5 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 111691009C3
  6. Ficha técnica de argatrobán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 74548C3
  7. Ficha técnica de bemiparina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 64166C3
  8. Ficha técnica de bivalirudina (250 mg, polvo para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 80912C3
  9. Ficha técnica de cangrelor (50 mg, polvo para solución inyectable y para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 115994001C3
  10. Ficha técnica de carvedilol (25 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 59695C3
  11. Ficha técnica de clopidogrel (75 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 98070001C3
  12. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08442002C3
  13. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08442003C3
  14. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08442005C3
  15. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08442006C3
  16. Ficha técnica de dabigatrán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08442007C3
  17. Ficha técnica de dabigatrán (150 mg, cápsulas). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08442011C3
  18. Ficha técnica de dalteparina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 62155C3
  19. Ficha técnica de digoxina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 34753C3
  20. Ficha técnica de digoxina (0,25 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 34566C3
  21. Ficha técnica de dobutamina (12,5 mg/mL, concentrado para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 85914C3
  22. Ficha técnica de edoxabán (60 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 115993018C3
  23. Ficha técnica de empagliflozina (10 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 114930014C7
  24. Ficha técnica de enoxaparina (10.000 UI (100 mg)/1 mL, jeringa precargada). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 62472C3
  25. Ficha técnica de esmolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 72349C3
  26. Ficha técnica de fondaparinux. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 02206006C3
  27. Ficha técnica de fondaparinux. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 02206014C3
  28. Ficha técnica de heparina sódica. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 58691C3
  29. Ficha técnica de levosimendán (2,5 mg/mL, concentrado para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 64154C3
  30. Ficha técnica de linagliptina (5 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 11707004C7
  31. Ficha técnica de liraglutida para el control del peso (6 mg/mL, pluma precargada). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 115992002B4B6C1C3C4C7C10D4H3I1I2
  32. Ficha técnica de milrinona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 58849C3
  33. Ficha técnica de naltrexona/bupropión. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 114988001B4C1C3C4C7I2
  34. Ficha técnica de orlistat. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 07401009B4C1C3C4I1I2
  35. Ficha técnica de orlistat. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 98071003B4C1C3C4C7I1I2
  36. Ficha técnica de prasugrel (10 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08503009C3
  37. Ficha técnica de propafenona (150 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 55538C3
  38. Ficha técnica de resmetirom. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1251962002C10
  39. Ficha técnica de rivaroxabán (20 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 08472021C3
  40. Ficha técnica de semaglutida (2,4 mg, pluma precargada). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1211608010B4B6C1C3C4C7C10D4H3I1I2
  41. Ficha técnica de semaglutida (7,2 mg, pluma precargada). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1211608025C3D4I2
  42. Ficha técnica de semaglutida (25 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1211608023B4B6C1C3C4C7D4I1I2
  43. Ficha técnica de setmelanotida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1211564001B4C3I1I2
  44. Ficha técnica de tenecteplasa. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 00169006C3
  45. Ficha técnica de tenecteplasa. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1000169007C3
  46. Ficha técnica de ticagrelor. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 110655013C3
  47. Ficha técnica de tinzaparina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 77153C3
  48. Ficha técnica de tirofibán (0,05 mg/mL, solución para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 62713C3
  49. Ficha técnica de tirzepatida (2,5 mg/dosis, pluma precargada). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1221685049B4B6C1C3C4C7C10D4H3I1I2
  50. Ficha técnica de vernakalant (20 mg/mL, concentrado para perfusión). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 10645002C3
  51. Ficha técnica de warfarina (5 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 63064C3
  52. Ficha técnica de ácido bempedoico (180 mg, comprimidos). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 18/11/2026. CIMA, registro 1201425002C7

Documentos oficiales (32)

  1. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Boletín sobre Seguridad de Medicamentos de Uso Humano. Junio de 2025. Consultado el 15/11/2026. aemps.gob.esI2
  2. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). La AEMPS informa de una reacción adversa ocular muy infrecuente en pacientes tratados con semaglutida. 2025. Consultado el 15/11/2026. aemps.gob.esI2
  3. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Boletín sobre Seguridad de Medicamentos de Uso Humano. Julio y agosto de 2024. Consultado el 15/11/2026. aemps.gob.esI2
  4. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Informes de posicionamiento terapéutico. Consultado el 15/11/2026. aemps.gob.esC2
  5. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Página de medicamentos ilegales. aemps.gob.esI2
  6. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Su nota. aemps.gob.esI2
  7. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Su nota. aemps.gob.esI2
  8. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Su nota. aemps.gob.esI2
  9. Ministerio de Sanidad. BIFIMED: buscador de la información sobre la situación de financiación de los medicamentos. Consultado el 15/11/2026. sanidad.gob.esC2C4
  10. Ministerio de Sanidad. Nomenclátor de facturación: productos incluidos en la prestación farmacéutica del SNS dispensables en oficinas de farmacia. Consultado el 15/11/2026. sanidad.gob.esC2
  11. Boletín Oficial del Estado (BOE). Orden PJC/798/2024, de 26 de julio, por la que se aprueba y publica el programa formativo de la especialidad de Medicina Familiar y Comunitaria, los criterios de evaluación de los especialistas en formación y los requisitos de acreditación de las Unidades Docentes Multiprofesionales de Atención Familiar y Comunitaria. Consultado el 15/11/2026. boe.esD3
  12. Boletín Oficial del Estado (BOE). Real Decreto 577/2013, de 26 de julio, por el que se regula la farmacovigilancia de medicamentos de uso humano. Consultado el 15/11/2026. boe.esI2
  13. Boletín Oficial del Estado (BOE). Real Decreto 1015/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales. Consultado el 15/11/2026. boe.esC2
  14. Boletín Oficial del Estado (BOE). Orden SCO/1259/2007, de 13 de abril, por la que se aprueba y publica el programa formativo de la especialidad de Cardiología. Consultado el 15/11/2026. boe.esD3
  15. Boletín Oficial del Estado (BOE). Real Decreto 618/2007, de 11 de mayo, por el que se regula el procedimiento para el establecimiento, mediante visado, de reservas singulares a las condiciones de prescripción y dispensación de los medicamentos. Consultado el 15/11/2026. boe.esC2
  16. Boletín Oficial del Estado (BOE). Real Decreto 1030/2006, de 15 de septiembre, por el que se establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actualización. Consultado el 15/11/2026. boe.esC2
  17. Boletín Oficial del Estado (BOE). Orden SCO/227/2007, de 24 de enero (BOE núm. 33, de 7 de febrero de 2007). boe.esD3
  18. Boletín Oficial del Estado (BOE). Orden SCO/3122/2006, de 20 de septiembre (BOE núm. 243, de 11 de octubre de 2006). boe.esD3
  19. Instituto Nacional de Estadística (INE). Encuesta de Salud de España (ESdE). Año 2025. Consultado el 15/11/2026. ine.esH2
  20. Instituto Nacional de Estadística (INE). INE: índice de masa corporal de la población adulta según sexo y comunidad autónoma, 2025. ine.esH2
  21. Agencia Europea de Medicamentos (EMA). Buscador de medicamentos. Consultado el 15/11/2026. ema.europa.euG5
  22. Agencia Europea de Medicamentos (EMA). Comienzo de la revisión de los arGLP-1 y las ideas de suicidio (julio de 2023), en inglés. ema.europa.euI2
  23. Agencia Europea de Medicamentos (EMA). Guía de la EMA para evaluar los fármacos del control del peso. ema.europa.euC5
  24. Agencia Europea de Medicamentos (EMA). La nota de la EMA, en inglés. ema.europa.euI2
  25. Agencia Europea de Medicamentos (EMA). Página de la EMA. ema.europa.euC5
  26. Agencia Europea de Medicamentos (EMA). Página de la EMA. ema.europa.euC5
  27. Agencia Europea de Medicamentos (EMA). Página de la EMA. ema.europa.euC5
  28. Agencia Europea de Medicamentos (EMA). Su nota, en inglés. ema.europa.euI2
  29. Food and Drug Administration (FDA, Estados Unidos). Borrador de su guía para desarrollar fármacos para reducir el peso. fda.govC5
  30. Food and Drug Administration (FDA, Estados Unidos). Drugs@FDA: base de datos de los medicamentos aprobados por la FDA. Consultado el 15/11/2026. accessdata.fda.govG5
  31. Food and Drug Administration (FDA, Estados Unidos). Su comunicación, en inglés. fda.govI2
  32. National Institute for Health and Care Excellence (NICE, Reino Unido). Overweight and obesity management (NG246). 2025. Consultado el 15/11/2026. nice.org.ukB3B4B6C4C7D4G1H4H5

Estudios registrados (ClinicalTrials.gov) (81)

  1. ACTIVATE-HFpEF. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07920887. NCT07920887G5
  2. ADVANCE-ATTAIN-ADOLESCENTS. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06672939. NCT06672939G5
  3. AMAZE 1. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07339423. NCT07339423G5
  4. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight. ClinicalTrials.gov, NCT07533175; activo, sin reclutar; fase 3; 638 participantes previstos; variable principal prevista para el 07/08/2028. Consultado el 15/11/2026. NCT07533175G5
  5. AMAZE 3. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07571005. NCT07571005G5
  6. AMAZE 4. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07571109. NCT07571109G5
  7. AMAZE 5. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07481630. NCT07481630G5
  8. AMAZE 6. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07509307. NCT07509307G5
  9. AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight. ClinicalTrials.gov, NCT07400107; activo, sin reclutar; fase 3; 985 participantes; variable principal prevista para el 19/12/2028. Consultado el 15/11/2026. NCT07400107G5
  10. AMBIENCE. A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity. ClinicalTrials.gov, NCT07861100; aún sin reclutar; fase 3; 8.500 participantes previstos; variable principal prevista para el 16/09/2030. Consultado el 15/11/2026. NCT07861100G5
  11. ATTAIN-Hypertension GZL1. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06948435. NCT06948435G5
  12. ATTAIN-Hypertension GZL2. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06952530. NCT06952530G5
  13. ATTAIN-NOW. A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity. ClinicalTrials.gov, NCT07794579; en reclutamiento; fase 3; 2.001 participantes previstos; variable principal prevista para agosto de 2029. Consultado el 15/11/2026. NCT07794579G5
  14. ATTAIN-OA PAIN. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07153471. NCT07153471G5
  15. ATTAIN-Outcomes. A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes). ClinicalTrials.gov, NCT07241390; en reclutamiento; fase 3; 7.140 participantes previstos; variable principal prevista para agosto de 2031. Consultado el 15/11/2026. NCT07241390G5
  16. ATTAIN-PAD. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease. ClinicalTrials.gov, NCT07223593; en reclutamiento; fase 3; 1.205 participantes previstos; variable principal prevista para junio de 2028. Consultado el 15/11/2026. NCT07223593G5
  17. DUAL-HFrEF. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07738276. NCT07738276G5
  18. ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease. ClinicalTrials.gov, NCT07850063; aún sin reclutar; fase 3; 600 participantes previstos; variable principal prevista para el 29/04/2029. Consultado el 15/11/2026. NCT07850063G5
  19. Enith-MACE. A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease. ClinicalTrials.gov, NCT07918846; aún sin reclutar; fase 3; 8.200 participantes previstos; variable principal prevista para el 20/03/2031. Consultado el 15/11/2026. NCT07918846G5
  20. Enith1. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07351045. NCT07351045G5
  21. Enith2. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07351058. NCT07351058G5
  22. ENLIGHTEN-10. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk. ClinicalTrials.gov, NCT07900633; aún sin reclutar; fase 3; 3.000 participantes previstos; variable principal prevista para noviembre de 2029. Consultado el 15/11/2026. NCT07900633G5
  23. ENLIGHTEN-3. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07369011. NCT07369011G5
  24. ENLIGHTEN-4. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07353931. NCT07353931G5
  25. FIT-HF. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06423599. NCT06423599G5
  26. GLORY-YOUNG. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07255209. NCT07255209G5
  27. HF-POLARIS. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity. ClinicalTrials.gov, NCT07567001; en reclutamiento; fase 3; 5.610 participantes previstos; variable principal prevista para el 23/07/2029. Consultado el 15/11/2026. NCT07567001G5
  28. MARITIME-1. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06858839. NCT06858839G5
  29. MARITIME-1-EXTENSION. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07684235. NCT07684235G5
  30. MARITIME-2. Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. ClinicalTrials.gov, NCT06858878; activo, sin reclutar; fase 3; 1.105 participantes; variable principal prevista para el 21/01/2027. Consultado el 15/11/2026. NCT06858878G5
  31. MARITIME-2-EXTENSION. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07684144. NCT07684144G5
  32. MARITIME-CV. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity. ClinicalTrials.gov, NCT07037433; activo, sin reclutar; fase 3; 12.800 participantes previstos; variable principal prevista para el 30/06/2028. Consultado el 15/11/2026. NCT07037433G5
  33. MARITIME-HF. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity. ClinicalTrials.gov, NCT07037459; en reclutamiento; fase 3; 5.056 participantes previstos; variable principal prevista para el 30/06/2028. Consultado el 15/11/2026. NCT07037459G5
  34. MARITIME-OSA-1. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07225686. NCT07225686G5
  35. MARITIME-OSA-2. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07226765. NCT07226765G5
  36. OASIS 5. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07770841. NCT07770841G5
  37. OBA. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07411378. NCT07411378G5
  38. PLATEAU. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07446998. NCT07446998G5
  39. PROACT. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07101939. NCT07101939G5
  40. QUALITY. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06282458. NCT06282458G5
  41. REDEFINE. A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity. ClinicalTrials.gov, NCT07919405; aún sin reclutar; fase 3; 1.408 participantes previstos; variable principal prevista para el 01/06/2028. Consultado el 15/11/2026. NCT07919405G5
  42. REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels. ClinicalTrials.gov, NCT05669755; activo, sin reclutar; fase 3; 7.101 participantes; variable principal prevista para el 01/09/2027. Consultado el 15/11/2026. NCT05669755G2G5
  43. REST. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07294950. NCT07294950G5
  44. SLIMMER-YOUNG. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07836270. NCT07836270G5
  45. SURMOUNT-ADOLESCENTS-2. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06439277. NCT06439277G5
  46. SURMOUNT-MMO. A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity. ClinicalTrials.gov, NCT05556512; activo, sin reclutar; fase 3; 15.374 participantes; variable principal prevista para octubre de 2027. Consultado el 15/11/2026. NCT05556512C4C5G2G5H3
  47. SYNERGY-Outcomes. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07165028. NCT07165028G5
  48. TRIUMPH-3. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease. ClinicalTrials.gov, NCT05882045; completado; fase 3; 1.946 participantes; terminó el 16/04/2026. Consultado el 15/11/2026. NCT05882045G5
  49. TRIUMPH-5. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. ClinicalTrials.gov, NCT06662383; activo, sin reclutar; fase 3; 800 participantes previstos; variable principal prevista para noviembre de 2026. Consultado el 15/11/2026. NCT06662383G5
  50. TRIUMPH-6. A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity. ClinicalTrials.gov, NCT06859268; activo, sin reclutar; fase 3; 643 participantes previstos; variable principal prevista para abril de 2028. Consultado el 15/11/2026. NCT06859268G5
  51. TRIUMPH-Outcomes. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). ClinicalTrials.gov, NCT06383390; activo, sin reclutar; fase 3; 10.000 participantes previstos; variable principal prevista para febrero de 2029. Consultado el 15/11/2026. NCT06383390G2G5
  52. VESPER-SWITCH. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07845500. NCT07845500G5
  53. ZUPREME-5. A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease. ClinicalTrials.gov, NCT07843472; en reclutamiento; fase 3; 2.500 participantes previstos; variable principal prevista para el 28/07/2030. Consultado el 15/11/2026. NCT07843472G5
  54. A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening). ClinicalTrials.gov, NCT06948422; activo, sin reclutar; fase 3; 974 participantes previstos; variable principal prevista para septiembre de 2027. Consultado el 15/11/2026. NCT06948422G5
  55. A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease. ClinicalTrials.gov, NCT07551492; en reclutamiento; fase 3; 9.262 participantes previstos; variable principal prevista para el 24/05/2031. Consultado el 15/11/2026. NCT07551492G5
  56. Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity. ClinicalTrials.gov, NCT07469800; en reclutamiento; fase 3; 336 participantes previstos; variable principal prevista para el 01/08/2026 (fecha ya pasada). Consultado el 15/11/2026. NCT07469800G5
  57. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT00263042. NCT00263042C5G2
  58. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT03574597. NCT03574597C5
  59. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT04822181. NCT04822181G2
  60. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06098079. NCT06098079G2
  61. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06131437. NCT06131437G5
  62. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06391710. NCT06391710G5
  63. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06565871. NCT06565871G5
  64. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06571383. NCT06571383G5
  65. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06643728. NCT06643728G5
  66. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06672549. NCT06672549G5
  67. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06780449. NCT06780449G5
  68. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06884293. NCT06884293G5
  69. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06903923. NCT06903923G5
  70. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06931028. NCT06931028G5
  71. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06974851. NCT06974851G5
  72. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT06994650. NCT06994650G5
  73. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07011667. NCT07011667G5
  74. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07253285. NCT07253285G5
  75. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07387094. NCT07387094G5
  76. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07434050. NCT07434050G5
  77. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07564414. NCT07564414G5
  78. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07575399. NCT07575399G5
  79. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07734311. NCT07734311G5
  80. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07817875. NCT07817875G5
  81. Estudio registrado en ClinicalTrials.gov. ClinicalTrials.gov, NCT07859176. NCT07859176G5
La lista se hace sola con lo que citan las páginas de este ESPACIO (PubMed por el PMID; el DOI, en PubMed o en Crossref; las fichas técnicas, en CIMA; los documentos oficiales, en la web de cada organismo; los estudios, en su registro de ClinicalTrials.gov) y se rehace cada vez que se actualiza el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

ESPACIO formativo de CardioTeca.com sobre obesidad. Contenidos elaborados con independencia editorial y dirigidos a profesionales sanitarios. Los fármacos se nombran por su denominación común internacional. Edita y revisa el Comité Editorial de CardioTeca. Última actualización: .

Comité científico · Independencia editorial · Preguntas sobre el ESPACIO

Cuenta gratuitapara profesionales sanitarios

Únete a la comunidad CardioTeca

Ya somos más de 27.000 profesionales. Crear tu cuenta te lleva un par de minutos.

Ejemplo de página profesional en CardioTeca
  • Accede sin límites a todos los contenidos y servicios de CardioTeca.
  • Tu página profesional, con tu foto, tus servicios, currículum, web y pedir cita.
  • Medicamentos, guías interactivas y calculadoras para el día a día.
  • Recibe en tu mail casos clínicos, comentarios de expertos y todas las novedades.
Ejemplo de página profesional en CardioTeca